Popular terms

Autoimmune Disease topics
Autoimmune Disease
Immune Disease
Autoimmune
Autoimmune Diseases
Immune Diseases
Transplant
Infectious Disease
Infectious
Inflammatory Disease
Antagonist
Rheumatoid Arthritis
Proliferative
Nucleotide
Antibodies
Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Disease patents



      

This page is updated frequently with new Autoimmune Disease-related patent applications.




Date/App# patent app List of recent Autoimmune Disease-related patents
06/16/16
20160168254 
 Rna-coded antibody patent thumbnailRna-coded antibody
The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160168248 
 Regulatory t cell mediator proteins and uses thereof patent thumbnailRegulatory t cell mediator proteins and uses thereof
In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. Multiple sclerosis is disclosed.

06/16/16
20160168149 
 Purinone compounds as kinase inhibitors patent thumbnailPurinone compounds as kinase inhibitors
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc


06/16/16
20160168083 
 Therapeutic compounds patent thumbnailTherapeutic compounds
Or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula i, processes for preparing compounds of formula i, intermediates useful for preparing compounds of formula i and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula i..

06/16/16
20160166708 
 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer patent thumbnailPro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.


06/16/16
20160166692 
 Rna-coded antibody patent thumbnailRna-coded antibody
The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160166691 
 Rna-coded antibody patent thumbnailRna-coded antibody
The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160166690 
 Rna-coded antibody patent thumbnailRna-coded antibody
The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/16/16
20160166664 
 Compositions and methods for induction of antigen-specific tolerance patent thumbnailCompositions and methods for induction of antigen-specific tolerance
The present invention utilizes carrier particles to present antigen peptides and proteins to the immune system in such a way as to induce antigen specific tolerance. The carrier particle is designed in order to trigger an immune tolerance effect.
Northwestern University


06/16/16
20160166636 
 Modified peptides and their use for treating chronic inflammatory diseases patent thumbnailModified peptides and their use for treating chronic inflammatory diseases
The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence ihmvyskrsgkprgyafiey, comprising one or more post-translational modifications, for the treatment, prevention or amelioration of a hyper autophagy-related autoimmune disease or disorder.. .
Centre National De La Recherche Scientifique


06/16/16
20160166611 

Method of preparing injection solution


A method of preparing an injection solution includes: (1) storing a mixture of a blood sample and a divalent cation chelating agent at a temperature between 2 and 12 degrees celsius for a period of from 3 hours to 72 hours so as to have the mixture with two or more separate layers, wherein a liquid in one of the separate layers contains small somatic stem cells such as sb cells; (2) collecting the liquid from the mixture; and (3) after collecting the liquid from the mixture, mixing the liquid with a solution free from ca2+ into the injection solution. The injection solution can be used for an autoimmune disease, such as ankylosing spondylitis, rheumatoid arthritis, or grover's disease..
Stembios Technologies, Inc.


06/09/16
20160160220 

Methods and compositions for treating autoimmune disorders by targeting kv1.3 ion channels with functionalized lipid-derived nanovesicles


Synthesis and pharmaceutical compositions of antibody-functionalized nanovesicles encapsulating ion channel knockout sirna, and methods of treating autoimmune diseases associated with increased expression and/or hyperactivity of t cells by selectively targeting memory t cells with the nanoparticles, which deliver their sirna cargo into the cytosol of the tm cell thus reducing ion channel expression and decreasing ca2+ influx.. .
North Carolina Agricultural And Technical State University


06/09/16
20160160218 

Use of aptamers in therapy and/or diagnosis of autoimmune diseases


The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of seq id no. 1, seq id no.
Max-delbrueck-centrum Fuer Molekulare Medizin


06/09/16
20160159802 

18f-labelled folates


The present invention is directed towards new 18f-folate radiopharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within folate structures, as well as their precursors and their non-radioactive references, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
Merck & Cie


06/09/16
20160159775 

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv


06/09/16
20160158366 

Clathrin therapeutic for autoimmune diseases


The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating an autoimmune disease, condition, or disorder in vivo or in vitro..

06/09/16
20160158352 

Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans


The invention provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The invention also features kits for carrying out the methods of the invention..
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic


06/09/16
20160158318 

Methods for treating scleroderma by administering a soluble ctla4 molecule


The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a ctla4 molecule that block endogenous b7 molecules from binding their ligands.. .
Bristol-myers Squibb Company


06/09/16
20160158218 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


06/02/16
20160152951 

Regulatory b cells (tbregs) and their use


Regulatory b cells (tbreg) are disclosed herein. These regulatory b cells express cd25 (cd25+) a pan b cell marker such as b220 (b220+), and also express cd19 (cd19+).
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


06/02/16
20160152706 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/02/16
20160152704 

Cadherin 15 agonists


Cdh15 has been identified as a receptor for a peptide which has an inhibitory effect of the migration of t cells. Agonists of this receptor have applications in the treatment and/or prophylaxis of conditions associated with the migration of t-cells, including t cell auto-reactivity, t cell mediated chronic inflammatory disease and autoimmune disease.
The University Of Birmingham


06/02/16
20160152699 

Pan-elr+ cxc chemokine antibodies


Antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer..
Eli Lilly And Company


06/02/16
20160152691 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


06/02/16
20160151471 

Inducible regulatory t-cell generation for hematopoietic transplants


The present invention provides methods and compositions for converting non-tregs into tregs. The converted tregs are referred to as inducible tregs (itregs).
The Trustees Of The University Of Pennsylvania


05/26/16
20160146831 

Antibody and cytokine biomarker profiling for determination of patient responsiveness


Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness.
The Board Of Trustees Of The Leland Stanford Junior University


05/26/16
20160145346 

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


05/26/16
20160145335 

Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease


The present invention provides chimeric and humanized versions of anti-cd19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human cd19 antigen and that may mediate adcc, cdc, and/or apoptosis for the treatment of b cell diseases and disorders, such as, but not limited to, b cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (gvhd), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients..
Medimmune, Llc


05/26/16
20160145249 

Alxr agonist compound


The present invention provides a compound having alxr agonist activity. Specifically, the invention provides a compound having alxr agonist activity represented by general formula (i) wherein all the symbols are as defined in the specification, a salt thereof, a solvate thereof, or a prodrug thereof as well as an agent containing the same as an active ingredient for preventing and/or treating an alxr-associated disease, such as an inflammatory bowel disease, an autoimmune disease, a chronic inflammatory disease, asthma, pulmonary fibrosis, atopic dermatitis, ischemia-reperfusion injury, myocardial infarction, or alzheimer's disease..
Ono Pharmaceutical Co., Ltd.


05/26/16
20160143870 

Ido inhibitors


There are disclosed compounds of formula (i) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.. .
Bristol-myers Squibb Company


05/19/16
20160138021 

Compositions and methods for treating cancer and other diseases


Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity.
Memorial Sloan Kettering Cancer Center


05/19/16
20160137731 

Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor


The present invention is based, in part, on the identification of novel human anti-pd-1, pd-l1, and pd-l2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating pd-1, pd-l1, and/or pd-l2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-pd-1, pd-l1, and pd-l2 antibodies described herein..
Emory University


05/19/16
20160137713 

Fcrn-specific human antibody and composition for treatment of autoimmune diseases


The present invention relates to a human antibody specific for fcrn that is a receptor with a high affinity for igg, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The fcrn-specific antibody according to the present invention can bind to fcrn non-competitively with igg or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases..
Hanall Biopharma Co., Ltd.


05/19/16
20160137646 

Novel compounds and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iv), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of formulae (i)-(iv) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.


05/19/16
20160137613 

Novel anti-inflammatory agents


Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (il-6) and/or vascular cell adhesion molecule-1 (vcam-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation..
Resverlogix Corp.


05/19/16
20160137608 

Substituted benzoazepines as toll-like receptor modulators


Provided are compositions and methods useful for modulation of signaling through the toll-like receptors tlr7 and/or tlr8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease..
Array Biopharma, Inc.


05/19/16
20160136267 

Sphingoglycolipid analogues


The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.. .
Victoria Link Limited


05/12/16
20160131646 

Detection and treatment of autoimmune disorders


Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (sle) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a pd1 ligand.. .
Seattle Children's Hospital


05/12/16
20160130552 

Method for obtaining immuno-suppressive dendritic cells


The present invention relates to methods for producing immuno-suppressive dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from autoimmune diseases, hypersensitivity diseases, rejection on solid-organ transplantation and/or graft-versus-host disease..
Yale University


05/12/16
20160130360 

Her2/neu-specific antibodies and methods of using same


This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.


05/12/16
20160130343 

Anti-ilt7 antibody


An antibody binding to ipc was obtained by using an animal cell in which a cell membrane protein associatable with ilt7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ilt family molecules and ilt7.
Sbi Biotech Co., Ltd.


05/12/16
20160130333 

Chimeric and humanized anti-histone antibodies


The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.


05/12/16
20160130318 

Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases


The present relates to interleukin 15 (il-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an il-15 mutant polypeptide having the amino acid sequence as set forth in seq id no:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.
Universite D'angers




Autoimmune Disease topics: Autoimmune Disease, Immune Disease, Autoimmune, Autoimmune Diseases, Immune Diseases, Transplant, Infectious Disease, Infectious, Inflammatory Disease, Antagonist, Rheumatoid Arthritis, Proliferative, Nucleotide, Antibodies, Infectious Diseases

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.4144

5549

0 - 1 - 102